Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.

International journal of molecular sciences - 19 May 2024

Ham Jae Min, Kim Myeongbin, Kim Taeho, Ryu Seong Eon, Park Hwangseo

Abstract excerpt

Being a component of the Ras/Raf/MEK/ERK signaling pathway crucial for cellular responses, the VRAF murine sarcoma viral oncogene homologue B1 (BRAF) kinase has emerged as a promising target for anticancer drug discovery due to oncogenic mutations that lead to pathway hyperactivation. Despite the discovery of several small-molecule BRAF kinase inhibitors targeting oncogenic mutants, their clinical utility has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Models, Molecular

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 38791574
DOI: 10.3390/ijms25105535
PMCID: PMC11122373

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.PMID 38791574Read ↗

De novo protein design enables targeting of intractable oncogenic interfacesSemantic proximity Read ↗

BRAF oncogenic mutants evade autoinhibition through a common mechanism.Semantic proximity Read ↗

In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.Semantic proximity Read ↗

Computer-guided design of Z domain peptides with improved inhibition of VEGFSemantic proximity Read ↗

Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of NelfinavirSemantic proximity Read ↗

Structure-based prediction of BRAF mutation classes using machine-learning approaches.Semantic proximity Read ↗

Identification of type II inhibitors targeting BRAF using privileged pharmacophores.Semantic proximity Read ↗

Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.Semantic proximity Read ↗

Functional characterization of a PROTAC directed against BRAF mutant V600E.Semantic proximity Read ↗

New insights into Raf regulation from structural analyses.Semantic proximity Read ↗

Optimizing the resveratrol fragments for novel in silico hepatocellular carcinoma de novo drug designSemantic proximity Read ↗

Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.